Celgene, Teva, others back dismissing US antitrust claims over Thalomid, Revlimid
MLex Summary: Celgene, Teva, AbbVie and others filed a reply in support of dismissing US claims that they conspired to illegally monopolize the market for Thalomid and Revlimid. The drugmakers say...To view the full article, register now.
Already a subscriber? Click here to view full article